SPECTRUM PHARMACEUTICALS INC

Form SC 13G/A January 08, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ___)*

Spectrum Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$.001 par value

(Title of Class of Securities)

84763A108

(CUSIP Number)

December 31, 2009

(Date of Event which Requires Filing of this

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Statement)

[X] Rule 13d-1(b)
[] Rule 13d-1(c)
[] Rule 13d-1(d)

Page 1 of 3

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

	SCHEDULE 13G	
CUSIP No.84763A108		Page 2 of 3 Pages

1	NAME OF REF		G PERSON DENTIFICATION NO. OF ABOVE PERSON				
	OTA LLC 13-3545927						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) []						
				(b)	[]	 	
3	SEC USE ONI	ĽΥ					
4	CITIZENSHIF	OR P	LACE OF ORGANIZATION				
	DELAWARE, U	JSA					
		5	SOLE VOTING POWER				
			1612619				
NUMBER OF SHARES BENEFICIALLY		6	SHARED VOTING POWER				
	D BY CH	7	SOLE DISPOSITIVE POWER				
REPORTING PERSON			1612619				
WI	TH	8	SHARED DISPOSITIVE POWER				
9	AGGREGATE A	AMOUNT	BENEFICIALLY OWNED BY EACH REPORTING PERS	ON			
	1612619						
10	CHECK BOX I	F THE	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERI	`AIN	[]		
11	PERCENT OF	CLASS	REPRESENTED BY AMOUNT IN ROW (9)				
	3.304%**						
12	TYPE OF REF	ORTIN					
	BD						

^{**}Calculation of the reporting person's percentage ownership is based on an approximate number of outstanding shares from the issuer's most recently filed quarterly or annual report.

Page 3 of 3

Tt.em	1(a).	Name o) f	Issuer:	Spect.rum	Pharmaceuticals,	. Inc.

- Item 2(a). Name of Person Filing: OTA LLC

IRS No. 13-3545927

- Item 2(b). Address of Principal Business ONE MANHATTANVILLE ROAD Office or, if None, Residence: PURCHASE, NY 10577
- Item 2(c). Citizenship:
 USA
- Item 2(d). Title of Class of Securities: Common Stock
- Item 2(e). CUSIP Number: 84763A108
- Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
 - (a) $|\mathbf{x}|$ Broker or dealer registered under Section 15 of the Exchange Act.
 - (b) $| _ |$ Bank as defined in Section 3(a)(6) of the Exchange Act.

 - (d) $|_|$ Investment company registered under Section 8 of the Investment Company Act.
 - (e) |_| An investment adviser in accordance with Rule 13d-1 (b) (1) (ii) (E);
 - (f) $|_|$ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
 - (g) $|_|$ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

 - (i) |_| A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
 - (j) $|_|$ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

The reporting person has, as of December 31, 2009 the right to acquire beneficial ownership of the common stock of the issuer within 60 days through the exercise of 1612619 warrants. The reporting person would beneficially own 1612619 common shares of the issuer upon the exercise of these warrants.

(b) Percent of class:

3.304%

This number represents the percentage ownership based on the right to acquire the common stock of the issuer within 60 days upon the exercise of the above referenced warrants.

- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or to direct the vote,

1612619 See Item 4(a)

- (ii) Shared power to vote or to direct the vote 0,
- (iii) Sole power to dispose or to direct the disposition of,

1612619 See Item 4(a)

- (iv) Shared power to dispose or to direct the disposition of 0
- Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following [X].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

N/A

Item 8. Identification and Classification of Members of the Group.

N/A

Item 9. Notice of Dissolution of Group.

N/A

Item 10. Certifications.

|X| (a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b):

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect."

(b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1 (c):

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect."

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

(Date)

/s/ JOHN HANRATTY

(Signature)

JOHN HANRATTY, CHIEF COMPLIANCE OFFICER

(Name/Title)

January 08, 2010

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).